January 29, 2018 05:38 AM ESTUpdated 10:23 AM

Sorry Novo: Sanofi wins Ablynx over with $4.8B buyout bid, bagging nanobody platform tech

Amber Tong

Sanofi $SNY has struck again — this time acquiring Ablynx, the Belgian biotech that has turned down two previous bids by Novo Nordisk, for $4.8 billion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sorry Novo: Sanofi wins Ablynx over with $4.8B buyout bid, bagging nanobody platform tech

Amber Tong

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Sor­ry No­vo: Sanofi wins Abl­ynx over with $4.8B buy­out bid, bag­ging nanobody plat­form tech

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sorry Novo: Sanofi wins Ablynx over with $4.8B buyout bid, bagging nanobody platform tech